Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid Leukemia

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 1, 2011, Pages 157-163

  Yamakawa, Y ^a   Hamada, A ^a,b   Shuto, T ^a   Yuki, M ^a   Uchida, T ^a   Kai, H ^a   Kawaguchi, T ^b   Saito, H ^a,b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AURANTIIN; IMATINIB; ORGANIC ANION TRANSPORTER 1;

ARTICLE; CELL STRAIN CACO 2; CELL STRAIN HEK293; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG TRANSPORT; DRUG UPTAKE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; PHARMACOGENETICS; PRIORITY JOURNAL;

ALGORITHMS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BLOTTING, WESTERN; CACO-2 CELLS; DNA; EPITHELIUM; FLAVANONES; GENOTYPE; HEK293 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; ORGANIC ANION TRANSPORTERS; PIPERAZINES; POLYMORPHISM, GENETIC; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79959372655     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.102     Document Type: Article

References (36)

1. Hagenbuch, B. & Meier, P.J. The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta 1609, 1-18 (2003). (Pubitemid 36044060)
2. Konig, J., Seithel, A., Gradhand, U. & Fromm, M.F. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch. Pharmacol. 372, 432-443 (2006).
3. Maeda, K. & Sugiyama, Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab. Pharmacokinet. 23, 223-235 (2008).
4. Kullak-Ublick, G.A. et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120, 525-533 (2001). (Pubitemid 32147650)
5. Franke, R.M., Scherkenbach, L.A. & Sparreboom, A. Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics 10, 339-344 (2009).
6. Kullak-Ublick, G.A. et al. Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 109, 1274-1282 (1995).
7. Lee, W. et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem. 280, 9610-9617 (2005). (Pubitemid 40409657)
8. Badagnani, I. et al. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J. Pharmacol. Exp. Ther. 318, 521-529 (2006). (Pubitemid 44061225)
9. Hartkoorn, R.C. et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet. Genomics 20, 112-120 (2010).
10. Cohen, M.H. et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8, 935-942 (2002). (Pubitemid 34520420)
11. Dagher, R. et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res. 8, 3034-3038 (2002). (Pubitemid 35155011)
12. Peng, B., Lloyd, P. & Schran, H. Clinical pharmacokinetics of imatinib. Clin. Pharmacokinet. 44, 879-894 (2005). (Pubitemid 41252840)
13. Picard, S. et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109, 3496-3499 (2007). (Pubitemid 46572540)
14. Larson, R.A. et al.; IRIS (International Randomized Interferon vs STI571) Study Group. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111, 4022-4028 (2008).
15. Thomas, J., Wang, L., Clark, R.E. & Pirmohamed, M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104, 3739-3745 (2004). (Pubitemid 39564452)
16. Hu, S. et al. Interaction of imatinib with human organic ion carriers. Clin. Cancer Res. 14, 3141-3148 (2008).
17. Franke, R.M. & Sparreboom, A. Inhibition of imatinib transport by uremic toxins during renal failure. J. Clin. Oncol. 26, 4226-4227; author reply 4227 (2008).
18. De Castro, W.V., Mertens-Talcott, S., Rubner, A., Butterweck, V. & Derendorf, H. Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies. J. Agric. Food Chem. 54, 249-255 (2006). (Pubitemid 43119947)
19. Bailey, D.G., Dresser, G.K., Leake, B.F. & Kim, R.B. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin. Pharmacol. Ther. 81, 495-502 (2007). (Pubitemid 46452308)
20. Meier, Y. et al. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab. Dispos. 35, 590-594 (2007). (Pubitemid 46513261)
21. Glaeser, H. et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther. 81, 362-370 (2007). (Pubitemid 46364477)
22. Kullak-Ublick, G.A. et al. Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain. FEBS Lett. 424, 173-176 (1998).
23. White, D.L. et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108, 697-704 (2006). (Pubitemid 44061372)
24. Wang, L., Giannoudis, A., Lane, S., Williamson, P., Pirmohamed, M. & Clark, R.E. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin. Pharmacol. Ther. 83, 258-264 (2008).
25. Iida, A. et al. Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteins. J. Hum. Genet. 46, 668-683 (2001). (Pubitemid 33134745)
26. Kawaguchi, T. et al. Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia. Int. J. Hematol. 89, 642-648 (2009).
27. Dresser, G.K. et al. Fruit juices inhibit organic anion transporting polypeptidemediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. 71, 11-20 (2002). (Pubitemid 34124034)
28. Cvetkovic, M., Leake, B., Fromm, M.F., Wilkinson, G.R. & Kim, R.B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27, 866-871 (1999). (Pubitemid 29347585)
29. Dresser, G.K., Kim, R.B. & Bailey, D.G. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin. Pharmacol. Ther. 77, 170-177 (2005). (Pubitemid 40269132)
30. Shirasaka, Y., Suzuki, K., Nakanishi, T. & Tamai, I. Intestinal absorption of HMGCoA reductase inhibitor pravastatin mediated by organic anion transporting polypeptide. Pharm. Res. 27, 2141-2149 (2010).
31. Gurney, H. et al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin. Pharmacol. Ther. 82, 33-40 (2007). (Pubitemid 46944197)
32. Dulucq, S. et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112, 2024-2027 (2008).
33. Y amakawa, Y. et al. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther. Drug Monit. 33, 244-250 (2011).
34. Takahashi, N. et al. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J. Hum. Genet. 55, 731-737 (2010).
35. Hamada, A., Miyano, H., Watanabe, H. & Saito, H. Interaction of imatinib mesilate with human P-glycoprotein. J. Pharmacol. Exp. Ther. 307, 824-828 (2003). (Pubitemid 37310701)
36. J udson, I. et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother. Pharmacol. 55, 379-386 (2005). (Pubitemid 40379262)